KPV
Research OnlyA naturally occurring tripeptide derived from the C-terminus of alpha-melanocyte-stimulating hormone (alpha-MSH). Preclinical studies demonstrate potent anti-inflammatory effects via NF-kB inhibition, but no human clinical trials have been conducted. Research has focused on inflammatory bowel disease and skin inflammation models.
Lys-Pro-Val · Lysine-Proline-Valine · alpha-MSH(11-13) · C-terminal alpha-MSH tripeptide
Mostly preclinical · 1 human study
- Preclinical
- 94%
- Clinical
- 6%
Based on 18 cited sources
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 19: highest human tier is animal-only (1A=6) — no human clinical study; the dossier's single "human" source is human cell lines (Caco2/HT29/Jurkat in 18061177), not a trial — so best-study RoB is high (1B=3), total human N<50 (1C=1), evidence indirect via animal models (1D=2); substantial multi-model preclinical program (DSS/TNBS colitis, peritonitis, contact hypersensitivity) earns 1E=7. Mechanism 67: PepT1 transporter functionally and genetically implicated (oral efficacy PepT1-dependent, MC1R-independence shown in MC1Re/e knockout mice, SHU9119 fails to block; 18061177/18092346/12750433) but the effector target lacks measured binding affinity (2A~25); NF-kB/IkBa pathway to gene transcription well mapped (2B=20); nanomolar dose-response across cell+in-vivo models (2C=13); confirmed in mouse models (2D=9). Plausibility 76: mechanism->surrogate (cytokine/MPO/histology) established in animals, surrogate->human benefit only inferred (3A=24); fully coherent with melanocortin/NF-kB anti-inflammatory biology (3B=24); class analogy via parent alpha-MSH and melanocortin peptides (3C=17); tightly scoped anti-inflammatory claim applied across tissues (3D=11). Global Coverage 48: independent replication across Emory(US), Munster(DE), London(UK), Houston(US), Dallas(US) groups (4A=22); 3+ countries (4B=13); ~18 studies with diverse contexts (4C=13); no regulatory recognition, research-only (4D=0). Community Experience 42: niche but persistent enthusiast use (5A=9), multi-year track record (5B=15), limited/consistent reports (5C=8), no notable adverse signal over modest exposure (5D=10). Effectiveness not-established: zero quantified human efficacy estimate and no meaningful documented community effect signal (dossier reports no positive/negative anecdotes).
The proposed mechanisms of KPV are based on animal models and cell culture studies. No human mechanistic data exists.
How It Works (Simplified)
KPV acts as an “inflammation brake” that works at the cellular level through several pathways:
Blocks the master inflammation switch by preventing IkBa degradation. Keeps NF-kB trapped in cytoplasm, unable to turn on inflammatory genes.
Uses intestinal peptide transporter PepT1 for cellular uptake - unusual for peptides and suggests potential oral bioavailability.
Reduces production of inflammatory messengers (TNF-alpha, IL-1, IL-6, IL-8) while potentially increasing anti-inflammatory IL-10.
Unlike parent alpha-MSH, KPV doesn’t bind melanocortin receptors. Provides anti-inflammatory benefits without skin pigmentation changes.
Key Research: Dalmasso G et al. demonstrated PepT1-mediated uptake is essential for KPV’s anti-inflammatory effects in colitis models. PMID:18061177
Important Limitations
- Nearly all mechanistic studies from limited research groups
- Translation to human physiology is unconfirmed
- Optimal administration route for systemic effects unknown
- Bioavailability and pharmacokinetics in humans not characterized
| NCT ID | Title | Peptide | Phase | Status | Completion |
|---|---|---|---|---|---|
| No registered trials | | KPV | Phase N/A | No clinical trials registered on ClinicalTrials.gov | - |
Based on preclinical data: NF-kB inhibition begins within hours of administration. Reduction in pro-inflammatory cytokine production (TNF-alpha, IL-1, IL-6) observed in cell studies. Animal colitis studies showed reduced inflammation markers within the first week.
PMID:9743348Animal studies demonstrate sustained anti-inflammatory effects with continued administration. Improved intestinal barrier function and reduced immune cell infiltration observed in colitis models.
PMID:18061177Preclinical models show ongoing suppression of inflammatory pathways. Oral bioavailability via PepT1 transporter enables sustained intestinal effects in animal studies.
PMID:18092346Long-term effects in humans are completely unknown. No clinical trials have established duration of treatment, optimal dosing, or sustained efficacy. All timeline data is extrapolated from short-term animal studies.
Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
BPC-157
CompatibleBoth have anti-inflammatory properties through different mechanisms. KPV targets NF-kB pathway while BPC-157 acts via VEGF/angiogenesis. No known contraindications.
LL-37
CompatibleLL-37's antimicrobial properties may complement KPV's anti-inflammatory effects in wound healing contexts. Different immune modulation mechanisms.
Thymosin-Alpha-1
CompatibleBoth modulate immune function through different pathways. KPV inhibits NF-kB while Ta1 enhances T-cell and dendritic cell responses. May have complementary effects.
GHK-Cu
CompatibleKPV's anti-inflammatory effects may complement GHK-Cu's wound healing and collagen synthesis properties. Different target pathways.
Melanotan-II
CautionBoth derive from melanocortin family. Unlike full alpha-MSH or Melanotan-II, KPV lacks melanocortin receptor binding. However, theoretical pathway overlap warrants caution.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare KPV
Related Peptides
Alpha-Defensins
HNP-1 · HNP-2 · HNP-3 +5
A family of small cationic antimicrobial peptides (29-35 amino acids) that are key components of innate immunity in humans. Produced primarily by neutrophils (HNP-1 to 4) and Paneth cells (HD-5, HD-6), they exhibit broad-spectrum antimicrobial activity and immunomodulatory functions. Well-characterized biochemically with extensive research, though therapeutic development faces challenges.
Kristagen
EDG · Glu-Asp-Gly · Immune tripeptide
A synthetic tripeptide (Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson, claimed to regulate thymus function and support immune cell differentiation. No Western clinical validation exists; research is limited to Russian preclinical studies.
Lactoferricin
LFcinB · Lactoferricin B · LfcinB +1
An antimicrobial peptide derived from lactoferrin, a protein found in milk and other secretions. Shows broad-spectrum antimicrobial activity in laboratory studies. Research focuses on potential applications in infectious disease, food safety, and cancer. Primarily studied preclinically with very limited human clinical data. Not approved as a therapeutic by any regulatory agency.
LL-37
Cathelicidin · hCAP18 · Human Cationic Antimicrobial Peptide 18 +3
The only human cathelicidin antimicrobial peptide, discovered at Karolinska Institute in Sweden (1995). A 37-amino acid peptide with broad-spectrum antimicrobial activity and immunomodulatory functions. Extensive mechanistic research supports roles in innate immunity, wound healing, and host defense.
Murepavadin
POL7080 · RG7929
A first-in-class cyclic antimicrobial peptide targeting the LptD outer membrane protein of Pseudomonas aeruginosa. The first OMPTA (outer membrane protein targeting antibiotic) to reach clinical development. IV formulation discontinued due to nephrotoxicity; inhaled formulation continues Phase 3 development for cystic fibrosis and bronchiectasis patients.
Thymalin
Thymulin · Thymic Factor · Timalin +1
A thymic peptide complex developed in Russia and used clinically in the former Soviet Union for immunomodulation. Derived from calf thymus extract, it contains multiple peptides claimed to restore immune function. Approved in Russia since the 1970s but not recognized by Western regulatory agencies. Evidence comes primarily from Russian studies with limited Western replication.